GPC3 and neoplasm: Portal Vein Injection of Anti‐GPC3 CAR‐T Cells Outperformed Systemic Delivery via Tail Vein, Effectively Suppressing Both Early‐Stage and Advanced Orthotopic HepG2 Tumour Growth